RIGEL PHARMACEUTICALS INC (RIGL) SEC Filings

RIGEL PHARMACEUTICALS INC (RIGL) executive David A. Santos, EVP and Chief Commercial Officer, had 874 shares of common stock delivered or withheld on September 1, 2026 to satisfy exercise price or tax liability at a reference value of $47.50 per share. Following this transaction, he directly holds 61,622 shares, which include 500 shares acquired under the company’s stock purchase plan. No Rule 10b5-1 trading plan is indicated for this filing.

RIGEL PHARMACEUTICALS INC (RIGL) reported that CEO and President Raul R. Rodriguez had 2,424 shares of common stock returned to the issuer on September 1, 2026 as a payment of exercise price or tax liability by delivering or withholding securities. The transaction price was $47.50 per share, and his directly held common stock position after this adjustment was 273,362 shares. A related footnote states that this reflects the return to the issuer of 3,807 shares previously reported as acquired under the issuer's employee stock purchase plan. No Rule 10b5-1 trading plan is reported for this transaction.

RIGEL PHARMACEUTICALS INC (RIGL) reported that executive vice president, general counsel, chief compliance officer and corporate secretary Raymond J. Furey had 877 shares of common stock disposed of on September 1, 2026 as a payment of exercise price or tax liability by delivering or withholding securities at $47.50 per share. After this transaction, he directly holds 50,559 shares of common stock, which includes 500 shares acquired under the issuer's stock purchase plan.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of Rigel Pharmaceuticals, Inc. common stock. They disclose beneficial ownership of 1,672,000 shares, representing 8.95% of the outstanding common stock as of June 30, 2026.

The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager, giving it shared voting and dispositive power over all 1,672,000 shares. Neither Armistice Capital nor Mr. Boyd has sole voting or dispositive power, and the Master Fund has the right to receive dividends and sale proceeds on these securities.

Soleus Capital Master Fund, L.P. and affiliated entities report beneficial ownership of Rigel Pharmaceuticals, Inc. common stock on an amended Schedule 13G. They report beneficial ownership of 1,843,504 shares of common stock, representing 9.9% of the class, based on 18,679,864 shares outstanding as of July 30, 2026.

The Soleus entities and Guy Levy report shared voting and dispositive power over all 1,843,504 shares and no sole voting or dispositive power. Each reporting person disclaims beneficial ownership of the shares beyond what is required for Section 13(d) reporting under the Exchange Act.

Rigel Pharmaceuticals reported second quarter 2026 total revenues of $78.7 million, including record net product sales of $67.0 million, up 14% year over year, and $11.7 million of contract revenues from collaborations. Net income was $17.3 million, or $0.88 per diluted share.

Growth in product sales was led by TAVALISSE at $47.4 million (up 18%) and REZLIDHIA at $8.9 million (up 27%), while GAVRETO declined to $10.7 million. Collaboration revenue reflected $5.8 million from Kissei, $5.0 million from Grifols and $0.3 million from Medison; the prior-year quarter included $40.0 million of non-cash revenue from a Lilly cost-share release, which lowered year-over-year reported revenues and earnings. For the first half of 2026, total revenues were $137.5 million and net income was $25.9 million.

Rigel entered an exclusive global license with Arvinas and Pfizer for VEPPANU, paying a $70.0 million upfront payment and preparing for U.S. commercial availability in mid-August 2026. Cash, cash equivalents and short-term investments were $95.3 million at June 30, 2026. The company raised its 2026 total revenue outlook to $285–$295 million, including $255–$265 million in net product sales and about $30 million in contract revenues, excluding VEPPANU, and continues to anticipate positive full-year net income.

Rigel Pharmaceuticals, Inc. reported total revenues of 78,703 (in thousands) for the quarter ended June 30, 2026, generating net income of 17,290 (in thousands), or $0.88 diluted earnings per share. For the first six months of 2026, revenues were 137,521 (in thousands) and net income was 25,944 (in thousands). Product sales grew, while contract revenues declined versus 2025, which had included a 39,981 (in thousands) release of a Lilly cost share liability.

Cash, cash equivalents, restricted cash and short-term investments totaled 95,386 (in thousands) at June 30, 2026, with stockholders’ equity of 425,422 (in thousands). The company repaid a prior term loan and entered a new revolving credit facility, with $40.0 million outstanding at quarter end. TAVALISSE net product sales were $84.7 million for the six months ended June 30, 2026, up 24% from $68.5 million, REZLIDHIA sales were $17.0 million, and GAVRETO sales were $20.3 million. Rigel licensed VEPPANU from Arvinas and Pfizer, paying a $70.0 million upfront fee and gaining rights to a fourth FDA-approved product expected to launch in mid-August 2026, while its prior global collaboration with Lilly for ocadusertib was terminated, with rights reverting to Rigel.

HANNAH ALISON L. reported acquisition or exercise transactions in this Form 4 filing.

RIGEL PHARMACEUTICALS INC reported that EVP and Chief Medical Officer Alison L. Hannah received a grant of 24,400 shares of common stock in the form of Restricted Stock Units. These RSUs vest annually over four years from July 8, 2026, with the first vesting on July 8, 2027. Following adjustments, including the cancellation of 5,750 RSUs for no consideration, she holds 35,025 shares of common stock directly.

Rigel Pharmaceuticals announced a leadership change in its top medical role. Alison L. Hannah, M.D. has been appointed Executive Vice President and Chief Medical Officer, effective July 1, 2026. At the same time, she resigned from Rigel’s Board of Directors, where she had served since May 2021.

Dr. Hannah has worked as a consultant to the pharmaceutical and biotechnology industry since 2000, focusing on investigational cancer therapies, and previously served as Chief Medical Officer of CytomX Therapeutics and Senior Medical Director at SUGEN, Inc. Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer and separated from Rigel effective June 25, 2026.